Home › Business & Finance › After capital-markets day flop, Novo strikes licensing...
Business & Finance

After capital-markets day flop, Novo strikes licensing deal that sends a Swedish company’s stock soaring

After capital-markets day flop, Novo strikes licensing deal that sends a Swedish company’s stock soaring
Key Points

Just days after a capital-markets day left investors wondering what’s next for Novo Nordisk, the Danish drug giant struck a licensing deal worth over $1 billion.

Just days after a capital-markets day left investors wondering what’s next for Novo Nordisk, the Danish drug giant struck a licensing deal worth over $1 billion. [Image text:] O R novo nordisk
Novo (ORG) Swedish (ORG) Novo Nordisk (ORG) Danish (ORG)
Originally published by MarketWatch Read original →